T cell receptor alpha variable 17Genealiases: TCRAV17S1 · TCRAV3S1
Q-omics provides the consensus-scored TRAV17 profile across patient tissues and cancer cell-line models. TRAV17 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRAV17 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, TRAV17 RNA expression shows 14,526 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight HNSC, KIRC, and DLBC as cancer lineages where TRAV17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAV17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAV17 survival associations across molecular data types. TRAV17 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAV17 RNA expression–survival associations across cancer types. High TRAV17 expression shows favorable associations in HNSC, SKCM, BRCA, OV, LUAD and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRAV17 RNA expression.
This table summarizes TRAV17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAV17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAV17 shows lower tumor expression in LUSC and COAD and higher tumor expression in KIRC, BRCA and CHOL. The KIRC box plot shows higher TRAV17 RNA expression in tumor versus normal tissue (log2 FC = +1.292, t-test p < 0.001).
This table shows molecular features associated with TRAV17 in patient tissues and cancer cell lines. In patient samples, TRAV17 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
